Fundraising Fox
🦊/Companies
Sign in

Acticor Biotech

2 known investors

Find your way into Acticor Biotech

Acticor Biotech develops Glenzocimab, a therapeutic candidate targeting GPVI for treating acute ischemic stroke and STEMI. The company is focused on cardiovascular and cerebrovascular indications.

BiotechDigital HealthMedical Devices

Founders & leadership

GAGilles AVENARD
Gilles AVENARDChief Executive Officer

Investors · 2

KaristaParis · $324K – $5.4M
Newton BiocapitalBrussels

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

ACTICOR BIOTECH raises €7M in addition to its series B financing, now completed at €22,3M - Go capitalgocapital.fr · Nov 2019Acticor Biotech Raises Additional €7M; Closes Series B At €22.3Mfinsmes.com · Nov 2019Acticor Biotech Raises €15.3M In a Series B Financing | AP Newsapnews.com · Oct 2018Acticor Biotech Secures €1,5 Million New Funding From CapDecisif Management - BioSpacebiospace.com · Feb 2017

Frequently asked questions

What does Acticor Biotech do?
Acticor Biotech develops Glenzocimab, a therapeutic candidate targeting GPVI for treating acute ischemic stroke and STEMI. The company is focused on cardiovascular and cerebrovascular indications.
Who founded Acticor Biotech?
Acticor Biotech was founded by Gilles AVENARD.
Who are Acticor Biotech's investors?
Acticor Biotech's investors include Karista, Newton Biocapital.